Strengthen TeamWork between IP Managers and Scientist: GALVmed, Commercialization of Vaccines in the Developing World Intellectual Property Management to support SECOPI-AGRO’s Agricultural Innovation Process Bogota, August 11-12th 2010 Monica Alandete-Saez, University California Davis, PIPRA
25
Embed
Intellectual Property Management to support SECOPI-AGRO’s Agricultural Innovation Process
Strengthen TeamWork between IP Managers and Scientist: GALVmed, Commercialization of Vaccines in the Developing World . Monica Alandete-Saez, University California Davis, PIPRA. Intellectual Property Management to support SECOPI-AGRO’s Agricultural Innovation Process - PowerPoint PPT Presentation
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Strengthen TeamWork between IP Managers and Scientist: GALVmed, Commercialization of
Vaccines in the Developing World
Intellectual Property Management to support SECOPI-AGRO’s Agricultural Innovation ProcessBogota, August 11-12th 2010
Monica Alandete-Saez,University California Davis, PIPRA
Technology TransferPublic
ResearchPrivate SectorPublic-Private
Partnership (PPPs)
Tech Transfer OfficeIP Management
Invention Investment CapitalRegulatory steps
Manufacture, etc.
Commercialization of a lucrative product (Agricultural or Health)
Interest in Profitable Market
Vaccine Commercialization
Regulatory Process has increased the cost of the vaccine development to very high IP Management
$$ Attract Private Sector
IP rights are essential for mobilizing the funds necessary
to meet the regulatory requirements
Vaccine Discovery
Registration
Commercialization
4.5 Years
Phase II
$8 M3 Years
Phase I
$4 M4 Years
Phase III
$160 M
R&D
Global Pharmaceutical Market and Neglected Diseases
Chapter 17.19. IP handbook of best practices
Availability: Vaccine needed predominantly by the poor do not receive high priority for R&D by the private sector
Cost: New vaccines are sold at prices beyond what the poor or their representatives can afford to pay
SynCo Bio Partners BV & Serum Institute of India Limited (SIIL)
US Food and Drugs
Administration (FDA)
Production of vaccine (charitable mssion) for
$0.40/doseAfrica
Product Development Partnerships
Global Access Strategies to introduce vaccine into developing countries
Discovery Research Development Registration Commer-
cialisationSustainedDelivery
Lack of funding for development
studies - high risk,
high cost.
Poorly designed, poorly controlled
field trials.
Unclear and varied
regulatory requirements.
Multiple regulatory authorities.
Inconsistent supply
Counterfeit products.
Lack of patent protection.
Poor quality and efficacy.
• R&D programs• IP Management and
licensing
• Safety regulations• Manufacture standards
GALVmed- The Global Alliance for Livestock Veterinary Medicines
A Global Not for Profit Organization
established under UK law based in Scotland
in 2005
GOAL: To develop, register and launch 4 to 6 vaccine, pharmaceutical, or diagnostic product by 2015 that meets the
needs of the world’s poorest livestock keepers
East Coast Fever Newcastle Disease Rift Valley Fever Porcine Cysticercosis
PIPRA:Freedom to Operate Reports Negotiations & Contracts with third parties
AcademyIndustry
GALVmed
PIPRA
• Pro Poor • Small dose package• Low price• Registered vaccine• Good Practice Manufacture• Sustainable Production
Animal vaccines
Public Sector
Introduction of ALL PARTIES involved in the project in a conference call
PIPRA
GALVmed
Very Important for success of the
projectto clarify
humanitarian mission from the
beginning
Vaccine Discovery
Registration
Commercialization
4.5 Years
Phase II
$8 M3 Years
Phase I
$4 M4 Years
Phase III
$160 M
FTO Analysis or IP Report
DE-CONSTRUCTION of Vaccine Development and Future Manufacture Process
IP Manager needs ALL details of invention, including location of MTAs. Long and could be a Frustrating
process
FTO Analysis or IP Report will have three possible outcomes:
2 - Continue project after CHANGING commercialization STRATEGY
3 - FINALIZE project
1 - Continue project after negotiating LICENSES
FTO Analysis is TERRITORIAL based in the commercialization strategy
Lower IP constraints Retain local talent and expertise Raise awareness in the community Support and enhance local research capacity Infrastructure remains in the community
Global Access Strategies. Benefits of Site R&D and Commercialization
Discovery Research Development Registration Commer-
cialisationSustainedDelivery
Types of VaccinesLive attenuated organisms which have been passed repeatedly
in tissue culture or chick embryos so that they have lost their capacity to cause disease, but retained an ability to induce antibody response. Potential reversion.
Inactivated or killed organisms which have been killed by heat or chemicals but retain and ability to induce antibody response. They are generally safe but less efficacious than live vaccines and require multiple doses.
Recombinant vaccines DNA sequences are inserted by molecular engineering techniques into a virus grown in cell culture.
Antigen Molecule recognized by the immune system capable to trigger an immune response.
Case Study I. Recombinant Vaccine: DNA sequence cloned into an inactivated virus
Case Study II. Diagnostic method
University created a recombinant vaccine that immunize animals and wanted to donate it to GALVmed, but did NOT PATENT it
Recently another University obtained a patent for use of such DNA sequence to develop vaccines in the territories chosen.
University is developing an immunoassay that detects the presence of an antigen that correlates with a disease.
R&D and Manufacture process used a cell expression system and a purification method covered by TPRs and IPRs
Case Study III. East Coast Fever Vaccine in Tanzania in 2010
Experimental vaccine against ECF was developed 30 years ago with major funding of UK’s Government Department of International
Development (DFID) and Bill & Melinda Gate Foundation
Aim is to REGESITER a vaccine to secure sustainable supply through commercialization
GALVmed is leading the registration, commercial distribution and delivery of the vaccine ($28M donated by DFID and Bill &
Melinda Gate Foundation)
The new ECF vaccine is an “infection-and treatment method”
Plant-Made Vaccines or TherapeuticsDefinition: Protein products with clinical or veterinary applications produced in recombinant plant systems
Major advantage of plant expression systems over the traditional vaccine production:• Reduced manufacturing Cost• Eliminates cross-contamination with animal diseases